News

Currie Medical to expand in Norfolk

Currie Medical, a medical device manufacturer, plans to invest $1.22 million to expand its operations in Norfolk, creating an estimated 60 jobs.

Based in Franklin, Tennessee, Currie Medical will lease a 30,000-square-foot building at 3701 E. Virginia Beach Blvd. in Norfolk, where it will house its medical device reprocessing operation and distribution center. Currie has 15 employees in Norfolk and employs about 45 people total between Virginia and Tennessee, according to co-owner Carter Smith. The new facility is expected to be in full operation and fully staffed in the first quarter of 2025, he added.

“Currie Medical is excited to expand our operations into the vibrant business community of Norfolk,” Smith and co-owner Owen Griffin said in a statement. “This region offers us a skilled workforce, strong infrastructure and a supportive environment that fosters growth and innovation in the medical technology sector. With this investment, we are committed to bringing new job opportunities to the area and continuing to develop new solutions in medical device reprocessing. We look forward to contributing to the advancement of health care with our growing Norfolk-based team.”

The Virginia Economic Development Partnership worked with the City of Norfolk and the Hampton Roads Economic Development Alliance to secure the project, and the Virginia Jobs Investment Program will assist Currie Medical with consultation and funding for recruitment and training activities. The company is also eligible for state benefits through the Port of Virginia Economic and Infrastructure Development Zone Grant Program.

“Currie Medical’s expansion in Norfolk highlights Virginia’s growing prowess in specialized manufacturing,” Gov. Glenn Youngkin said in a statement. “This project not only adds to our skilled workforce but also strengthens our reputation as a hub for innovative medical technology solutions. We are proud to have them in the commonwealth for years to come.”

Read more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and